Literature DB >> 11063829

Persistent accumulation of cyclooxygenase-1 (COX-1) expressing microglia/macrophages and upregulation by endothelium following spinal cord injury.

J M Schwab1, K Brechtel, T D Nguyen, H J Schluesener.   

Abstract

Acute inflammation following spinal cord injury results in secondary injury and pathological reorganisation of the central nervous system (CNS) architecture. Cyclooxygenases (Prostaglandin Endoperoxide H Synthases, PGH) are key enzymes in the conversion of arachidonic acid into prostanoids which mediate immunomodulation, mitogenesis, apoptosis, blood flow, secondary injury (lipid peroxygenation) and inflammation. Here, we report cyclooxygenase-1 (COX-1) expression following spinal cord injury. In control spinal cords, COX-1 expression was localized by immunohistochemistry to ependymal cells, some neurons, inclusive dorsal and ventral root ganglion cells, few endothelial cells but rarely to brain microglia/macrophages. In injured spinal cords, COX-1(+) microglia/macrophages accumulated highly significantly (P<0.0001) at peri-lesional areas and in the developing necrotic core early after injury. Here numbers of COX-1(+) cells remained persistently elevated up to 4 weeks following injury. Further, COX-1(+) cells were located in perivascular Virchow-Robin spaces, between spared axons and in areas of Wallerian degeneration. Double labeling experiments confirmed co-expression of COX-1 by ED-1(+) and OX-42(+) microglia/macrophages. Transiently after infarction most COX-1(+) microglia/macrophages coexpress the activation antigen OX-6 (MHC class II). However, the prolonged accumulation of COX-1(+) microglia/macrophages at the lesion site enduring the acute post injury inflammatory response points to a role of COX-1 in tissue remodeling or secondary injury. We have identified and localized persistent accumulation of COX-1 expressing cells which might be a potential pharmacological target following spinal cord injury. Therefore, we suggest that approaches based on: (i) short-term; and (ii) selective COX-2 blocking alone might not be a sufficient tool to suppress the local synthesis of prostanoids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063829     DOI: 10.1016/s0165-5728(00)00372-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  Neuroprotection and acute spinal cord injury: a reappraisal.

Authors:  Edward D Hall; Joe E Springer
Journal:  NeuroRx       Date:  2004-01

2.  Acute traumatic spinal cord injury induces glial activation in the cynomolgus macaque (Macaca fascicularis).

Authors:  A D Miller; S V Westmoreland; N R Evangelous; A Graham; J Sledge; S Nesathurai
Journal:  J Med Primatol       Date:  2012-06       Impact factor: 0.667

3.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

4.  Pharmacokinetics and anti-inflammatory effect of naproxen in rats with acute and subacute spinal cord injury.

Authors:  Arianna Rodríguez-Cal Y Mayor; Gilberto Castañeda-Hernández; Liliana Favari; Angelina Martinez-Cruz; Gabriel Guízar-Sahagún; Leticia Cruz-Antonio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-22       Impact factor: 3.000

5.  Tenoxicam modulates antioxidant redox system and lipid peroxidation in rat brain.

Authors:  Mustafa Naziroğlu; Abdulhadi Cihangir Uğuz; Alpaslan Gokçimen; Metin Bülbül; Dilek Ulusoy Karatopuk; Yasin Türker; Celal Cerçi
Journal:  Neurochem Res       Date:  2008-03-14       Impact factor: 3.996

Review 6.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

7.  Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury.

Authors:  Sang-Ho Choi; Robert Langenbach; Francesca Bosetti
Journal:  FASEB J       Date:  2007-12-27       Impact factor: 5.191

8.  Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli.

Authors:  Borja García-Bueno; Jordi Serrats; Paul E Sawchenko
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

Review 9.  The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury.

Authors:  Jan M Schwab; Yi Zhang; Marcel A Kopp; Benedikt Brommer; Phillip G Popovich
Journal:  Exp Neurol       Date:  2014-08       Impact factor: 5.330

10.  Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice.

Authors:  Matthew L Kelso; Stephen W Scheff; James R Pauly; Charles D Loftin
Journal:  BMC Neurosci       Date:  2009-08-31       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.